Skip to content
Biodatica
Start free

Verastem, Inc.

Scottsdale, Arizona

OncologyPhase IIIListed · VSTM

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

1w agoTrial registeredJul 13, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jun 20, 2024

    Ovarian Cancer Recurrent · RECRUITING · sponsor: Institute of Cancer Research, United Kingdom · SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

    ClinicalTrials.gov · NCT05990192 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Apr 29, 2024

    Low-Grade Serous Ovarian Cancer · RECRUITING · sponsor: Memorial Sloan Kettering Cancer Center · A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

    ClinicalTrials.gov · NCT06394804 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Mar 18, 2024

    Low Grade Serous Ovarian Cancer · RECRUITING · sponsor: Verastem, Inc. · A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

    ClinicalTrials.gov · NCT06072781 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jan 26, 2024

    Ovarian Cancer · ACTIVE_NOT_RECRUITING · sponsor: Memorial Sloan Kettering Cancer Center · A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy

    ClinicalTrials.gov · NCT06240598 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Mar 22, 2023

    KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas · ACTIVE_NOT_RECRUITING · sponsor: Verastem, Inc. · Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

    ClinicalTrials.gov · NCT05669482 (opens the source filing in a new tab)

  6. Trial

    PHASE2 registered

    Mar 15, 2023

    Mesonephric Gynecologic Cancer · RECRUITING · sponsor: Memorial Sloan Kettering Cancer Center · A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

    ClinicalTrials.gov · NCT05787561 (opens the source filing in a new tab)

  7. Trial

    PHASE1/PHASE2 registered

    Aug 1, 2022

    Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease · COMPLETED · sponsor: Verastem, Inc. · Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

    ClinicalTrials.gov · NCT05375994 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    Apr 12, 2022

    Non Small Cell Lung Cancer, KRAS Activating Mutation · ACTIVE_NOT_RECRUITING · sponsor: Verastem, Inc. · Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

    ClinicalTrials.gov · NCT05074810 (opens the source filing in a new tab)

  9. Trial

    PHASE2 registered

    Dec 21, 2020

    Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer · ACTIVE_NOT_RECRUITING · sponsor: Verastem, Inc. · A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

    ClinicalTrials.gov · NCT04625270 (opens the source filing in a new tab)

  10. Trial

    PHASE1 registered

    May 7, 2020

    Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

    ClinicalTrials.gov · NCT04092270 (opens the source filing in a new tab)

  11. Trial

    Study registered

    Feb 3, 2020

    Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · COMPLETED · sponsor: Royal Marsden NHS Foundation Trust · Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

    ClinicalTrials.gov · NCT04295577 (opens the source filing in a new tab)

  12. Trial

    PHASE2 registered

    May 2, 2019

    Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer · COMPLETED · sponsor: Memorial Sloan Kettering Cancer Center · A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

    ClinicalTrials.gov · NCT03909152 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources